Top Stocks Surge After Strong Q2 Results: Alnylam, Carvana, Air Products Lead
Generado por agente de IAAinvest Market Brief
jueves, 1 de agosto de 2024, 6:30 pm ET1 min de lectura
ALNY--
MS--
1. Alnylam Pharmaceuticals (Nasdaq: ALNY)
Alnylam Pharmaceuticals surged by 13.12%. Alnylam Pharmaceuticals reported its second quarter fiscal 2024 results on August 1. Cantor Fitzgerald, Morgan Stanley, and Canaccord Genuity all maintained their ratings on Alnylam Pharmaceuticals, with price targets set at $220.00, $255.00, and $357.00 respectively. Yvonne Greenstreet sold 7,093 shares on July 11.
2. Carvana (NYSE: CVNA)
Carvana surged by 10.05%. Carvana reported second-quarter fiscal 2024 results with revenue of $34 billion, net income of $48 million, and EPS of $0.14. Morgan Stanley maintains an Underweight rating, while Wells Fargo upgraded to Overweight at $175, and Needham maintains Buy at $200.
3. Air Products And Chemicals (NYSE: APD)
Air Products And Chemicals surged by 8.87%. Air Products and Chemicals will report its Third Quarter financial results for fiscal 2024 on August 1. Deutsche Bank downgraded the company to Hold and lowered the price target to $280. Citigroup maintains a Buy rating, raising the target to $305.
4. Iron Mountain Incorporated (NYSE: IRM)
Iron Mountain Incorporated surged by 6.83%. Iron Mountain reported its Second Quarter fiscal 2024 results on August 1, 2024. Wells Fargo maintains an Overweight rating with a price target of $110.00. Stifel maintains a Buy rating with a price target of $103.00. Recent insider transactions were disclosed in July.
5. Aflac Incorporated (NYSE: AFL)
Aflac Incorporated surged by 6.45%. Aflac's second quarter fiscal 2024 results showed net income attributable to common shareholders. B of A Securities maintains a Buy rating on Aflac, increasing the price target to $108.00. Citigroup and JP Morgan maintain neutral ratings with targets of $93.00 and $83.00, respectively.
Alnylam Pharmaceuticals surged by 13.12%. Alnylam Pharmaceuticals reported its second quarter fiscal 2024 results on August 1. Cantor Fitzgerald, Morgan Stanley, and Canaccord Genuity all maintained their ratings on Alnylam Pharmaceuticals, with price targets set at $220.00, $255.00, and $357.00 respectively. Yvonne Greenstreet sold 7,093 shares on July 11.
2. Carvana (NYSE: CVNA)
Carvana surged by 10.05%. Carvana reported second-quarter fiscal 2024 results with revenue of $34 billion, net income of $48 million, and EPS of $0.14. Morgan Stanley maintains an Underweight rating, while Wells Fargo upgraded to Overweight at $175, and Needham maintains Buy at $200.
3. Air Products And Chemicals (NYSE: APD)
Air Products And Chemicals surged by 8.87%. Air Products and Chemicals will report its Third Quarter financial results for fiscal 2024 on August 1. Deutsche Bank downgraded the company to Hold and lowered the price target to $280. Citigroup maintains a Buy rating, raising the target to $305.
4. Iron Mountain Incorporated (NYSE: IRM)
Iron Mountain Incorporated surged by 6.83%. Iron Mountain reported its Second Quarter fiscal 2024 results on August 1, 2024. Wells Fargo maintains an Overweight rating with a price target of $110.00. Stifel maintains a Buy rating with a price target of $103.00. Recent insider transactions were disclosed in July.
5. Aflac Incorporated (NYSE: AFL)
Aflac Incorporated surged by 6.45%. Aflac's second quarter fiscal 2024 results showed net income attributable to common shareholders. B of A Securities maintains a Buy rating on Aflac, increasing the price target to $108.00. Citigroup and JP Morgan maintain neutral ratings with targets of $93.00 and $83.00, respectively.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios